|
⚲
|
| Keyboard |
| Pura Vida Investments LLC
✚
|
|
|---|---|
| CRD # | 166703 |
| SEC # | 801-80547 |
| CIK # | 0001590144 |
| AUM | 91.5 M (2026-03-30) |
| Employees | 2 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 929-733-7678 |
| Address | 545 W 25th Street New York, NY 10001 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5. Fees and Compensation The Adviser charges certain of the Clients an investment management fee (the “Management Fee”) based on either the value of the Client’s assets under management or, for certain investments, the lower of the investment’s cost or market value. The Management Fee for Pura Vida Funds is generally payable to the Adviser monthly in advance and is at an annual rate of up to 2% of the value of each investor’s account as of the first day of the applicable month. The Management Fee will be prorated for any period that is less than a full month and will be adjusted for subscriptions. For the Pura Vida Funds, the Adviser instructs the Pura Vida Funds’ administrator to deduct the Management Fee from the relevant Pura Vida Fund’s account. In addition, the Clients are subject to carried interest or incentive allocation (collectively, the “Performance Fee”) as set forth in each Client’s Governing Documents and is equal to a specified percentage of all income, gains, and losses derived from portfolio investments. Either the Adviser or the general partner of the Pura Vida Funds (and/or a designee thereof) is paid or allocated the Performance Fee. In addition, the Clients may be subject to other expenses, such as legal, administration, accounting, auditing, insurance, proxy voting services and other professional expenses, investment expenses such as commissions, lobbying, research fees and expenses (including research-related travel); interest on margin accounts and other indebtedness; borrowing charges on securities sold short; custodial fees, bank service fees and other expenses related to the purchase, sale or transmittal of Client assets (including designated investments). It is important that each investor who is considering an investment in a Client review the Governing Documents applicable to that Client for a detailed description of the fees and expenses applicable to such investment. Investors should review carefully Item 12, which discusses conflicts of interest related to brokerage practices. The Adviser, in its sole discretion, may waive or reduce the Management Fee and/or the Performance Fee for investors including those that are members, employees or affiliates of the Adviser, relatives of such persons, and/or for certain strategic investors. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7. Types of Clients As described in Item 4, the Adviser’s clients are the Pura Vida Funds and Managed Accounts. Any initial and additional subscription minimums for investors in Pura Vida Funds are disclosed in each Pura Vida Fund’s Governing Documents. |
| CIK | Period |
|---|---|
| 0001590144 |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Oncocyte Corp | 0.0 | ||
| Beta Bionics Inc | 0.0 | ||
| Establishment Labs Holdings Inc | 0.0 | ||
| Caris Life Sciences Inc | 0.0 | ||
| InspireMD Inc | 0.0 | ||
| Natera Inc | 0.0 | ||
| Nvidia Corp | 0.0 | ||
| J P Morgan Chase & Co | 0.0 | ||
| Microsoft Corp | 0.0 | ||
| Metagenomi Inc | 0.0 | ||
| Alphabet Inc | 0.0 | ||
| Outset Medical Inc | 0.0 | ||
| Analog Devices Inc | 0.0 | ||
| Apple Inc | 0.0 | ||
| ASML Holding NV | 0.0 | ||
| Linde PLC | 0.0 | ||
| Amazon Com Inc | 0.0 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Pura Vida X Fund LP | [2022-03-30] | 17.5 M | 30.2 M |
| Filed 2021-07-02 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Pura Vida Pro Special Opportunity Master Fund Ltd | [2020-03-25] | 55.9 M | 1.9 M |
| Filed 2024-11-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Pura Vida Private Equity Fund LP | [2016-03-14] | 1.6 M | 18.9 M |
| Offered $1,610,000 · Filed 2016-01-05 (D) · Exemption 506(b) · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Pura Vida SPV I LLC | [2014-10-28] | 5.8 M | 14.1 M |
| Filed 2020-06-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Pura Vida Master Fund Ltd | [2013-01-24] | 257.6 M | 20.4 M |
| Filed 2024-11-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 52.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 2 | 39.0 |
| Total | 12 | 91.5 |
| By Discretionary | ||
| Discretionary | 12 | 91.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 12 | 91.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 20.4 | |
| United States Persons | 71.1 | |
| Total | 12 | 91.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Pura Vida Investments LLC | Executive Officer | 6 | 2 | |
| Pura Vida Funds Group GP LLC | Executive Officer | 5 | 2 | |
| Efrem Kamen | Executive Officer | 3 | 2 | |
| Pura Vida Pro LLC | Executive Officer | 1 | 1 | |
| Shayne Sowers | Executive Officer | 1 | 1 | |
| Narayan Krishnan | Executive Officer | 1 | 1 | |
| Pura Vida Pro GP LLC | Executive Officer | 1 | 1 | |
| Thomas Sowers | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001590144] | |
| 3 | [0001590144] | |
| 4 | [0001590144] | |
| 5 | [0001590144] | |
| SC 13D | [0001590144] | |
| SC 13G | [0001590144] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300D8Z5XG6F8J3C44 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Pura Vida Investments LLC | |
| Oncocyte Corp | |
| Kamen Efrem | |
| Pura Vida Master Fund LTD | |
| MedMen Enterprises Inc | |
| Stryve Foods Inc | |
| Greenlane Holdings Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Oncocyte Corp OCX
Common Stock
|
2023-04-05 | Buy | 663,000 | $0.30 | 198,900 |
|
Oncocyte Corp OCX
Common Stock
|
2023-03-06 | Other | 3,890,111 | ||
|
Oncocyte Corp OCX
Common Stock
|
2022-06-24 | Sell | 10,964 | $1.05 | 11,512 |
|
Oncocyte Corp OCX
Common Stock
|
2022-06-24 | Sell | 12,517 | $1.05 | 13,143 |
|
Oncocyte Corp OCX
Common Stock
|
2022-06-24 | Sell | 40,464 | $1.03 | 41,678 |
|
Oncocyte Corp OCX
Common Stock
|
2022-06-24 | Sell | 35,441 | $1.03 | 36,504 |
|
Oncocyte Corp OCX
Common Stock
|
2022-04-14 | Buy | 767,952 | $1.33 | 1,021,376 |
|
Oncocyte Corp OCX
Common Stock
|
2022-04-14 | Buy | 1,665,898 | $1.33 | 2,215,644 |
|
Oncocyte Corp OCX
Common Stock
|
2022-04-14 | Buy | 30,790 | $1.23 | 37,872 |
|
Oncocyte Corp OCX
Common Stock
|
2022-04-14 | Buy | 1,916,419 | $1.33 | 2,548,837 |
|
Oncocyte Corp OCX
Common Stock
|
2022-04-14 | Buy | 57,630 | $1.26 | 72,614 |
|
Oncocyte Corp OCX
Common Stock
|
2022-04-14 | Buy | 19,210 | $1.23 | 23,628 |
|
Oncocyte Corp OCX
Common Stock
|
2022-04-14 | Buy | 92,370 | $1.26 | 116,386 |
|
Oncocyte Corp OCX
Warrant to purchase common stock · derivative
|
2022-04-14 | Buy | 690,719 | ||
|
Oncocyte Corp OCX
Warrant to purchase common stock · derivative
|
2022-04-14 | Buy | 383,976 | ||
|
Oncocyte Corp OCX
Warrant to purchase common stock · derivative
|
2022-04-14 | Buy | 832,949 | ||
|
Oncocyte Corp OCX
Warrant to purchase common stock · derivative
|
2022-04-14 | Buy | 958,209 | ||
|
Oncocyte Corp OCX
Common Stock
|
2022-04-14 | Buy | 1,381,438 | $1.33 | 1,837,313 |
|
Stryve Foods Inc SNAX
Class A Common Stock
|
2021-09-15 | Sell | 800,000 | ||
|
Stryve Foods Inc SNAX
Prepaid Common Stock Purchase Warrant (right to buy) · derivative
|
2021-09-15 | Buy | 800,000 | ||
| showing 20 of 92 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Ridgeline Productions LLC
✚
|
NY | 115.4 M |
|
Islet Management LP
✚
|
NY | 108.8 M |
|
Kalamata Asset Management LLC
✚
|
MD | 106.8 M |
|
Stonebridge Partners LLC
✚
|
NY | 99.4 M |
|
Arex Capital Management LP
✚
|
NY | 99.4 M |
|
S Muoio & Co LLC
✚
|
NY | 95.1 M |
|
Oxford Gate Management LLC
✚
|
CT | 90.9 M |
|
Seaport Global Asset Management LLC
✚
|
NY | 80.0 M |
|
Shoreline Capital Management Ltd
✚
|
75.9 M | |
|
Abry Partners LLC
✚
|
MA | 69.3 M |